Abstract
• Targeted therapies improve clinical outcomes in HER2+ metastatic breast cancer. • There is thus far minimal signal of increased risk of cardiotoxicity from novel HER2 targeted therapies. • Cancer therapy benefit drives clinical decision-making with LV dysfunction. • The frequency of cardiac monitoring should be based on a risk-benefit approach.